■这项回顾性队列研究旨在评估临床特征,治疗结果,肾移植受者(KTRs)并发冠状病毒病2019(COVID-19)肺炎的短期预后。
■从2022年12月28日至2023年3月28日入院的患有COVID-19肺炎的KTR被纳入研究。他们的临床症状,对抗病毒药物的反应,并对近期预后进行分析。
■本研究共纳入了64例初步诊断为COVID-19肺炎的KTR。主要症状是发烧,咳嗽,和肌痛,发病率为79.7%,89.1%,和46.9%,分别。与没有抗病毒药物的组相比,在1-5天内和超过5天内给予抗病毒药物(paxlovid或molnupiravir)显示病毒脱落时间的统计学显着减少(P=0.002)。与不使用抗病毒药物的组相比,paxlovid和molnupiravir治疗组的病毒脱落时间均显着缩短(P=0.002)。经过6个月的恢复,对移植肾功能无显著负面影响(P=0.294).
■发烧,咳嗽,肌痛仍然是KTRs并发COVID-19肺炎的常见初始症状。早期使用抗病毒药物(paxlovid或molnupiravir)与更好的治疗效果相关。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)对并发中度或重度COVID-19肺炎的KTRs的短期肾功能影响有限。
UNASSIGNED: This retrospective cohort study aimed to assess the clinical features, treatment outcomes, and short-term prognosis in kidney transplant recipients (KTRs) with concurrent coronavirus disease 2019 (COVID-19) pneumonia.
UNASSIGNED: KTRs with COVID-19 pneumonia who were admitted to our hospital from December 28, 2022, to March 28, 2023 were included in the study. Their clinical symptoms, responses to antiviral medications, and short-term prognosis were analyzed.
UNASSIGNED: A total of 64 KTRs with initial diagnosis of COVID-19 pneumonia were included in this study. The primary symptoms were fever, cough, and myalgia, with an incidence of 79.7%, 89.1%, and 46.9%, respectively. The administration of antiviral drugs (paxlovid or molnupiravir) within 1-5 days and for over 5 days demonstrated a statistically significant reduction in viral shedding time compared to the group without antiviral medication (P=0.002). Both the paxlovid and molnupiravir treatment groups exhibited a significantly shorter duration of viral shedding time in comparison to the group without antiviral drugs (P=0.002). After 6 months of recovery, there was no significantly negative impact on transplant kidney function (P=0.294).
UNASSIGNED: Fever, cough, and myalgia remain common initial symptoms of concurrent COVID-19 pneumonia in KTRs. Early use of antiviral drugs (paxlovid or molnupiravir) is associated with better therapeutic outcomes. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a limited impact on the short-term renal function of the KTRs with concurrent moderate or severe COVID-19 pneumonia.